Free Trial

Seer Q2 2024 Earnings Report

Seer logo
$2.29 -0.02 (-0.87%)
As of 01/17/2025 04:00 PM Eastern

Seer EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.01
One Year Ago EPS
-$0.37

Seer Revenue Results

Actual Revenue
$3.07 million
Expected Revenue
$3.33 million
Beat/Miss
Missed by -$260.00 thousand
YoY Revenue Growth
N/A

Seer Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Seer Earnings Headlines

Must-See: 5-Second Trump Prediction
President Trump's prediction is about to become a reality... Opening a rare window of opportunity for you to accelerate your retirement during the first 100 days of his administration.
See More Seer Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Seer? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seer and other key companies, straight to your email.

About Seer

Seer (NASDAQ:SEER), a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

View Seer Profile

More Earnings Resources from MarketBeat